Photo credits
Why Valproate Still Matters
Valproate is the everyday anticonvulsant mood stabilizer: fast, flexible, and useful for the presentations where lithium struggles. Lithium owns the classic euphoric-mania-then-euthymia patient; valproate earns its keep in the messier part of the bipolar spectrum: mixed features, rapid cycling, irritable/dysphoric mania, and bipolar with comorbid substance use. You can load it quickly and dose it flexibly, you don't have to worry about the kidney the way you do with lithium, and it works for a substantial fraction of patients who never fit the Kraepelinian mold.
It is also one of the few mood stabilizers with a dual indication, FDA-approved for both bipolar mania and migraine prophylaxis, so it's a natural pick for the bipolar patient who also gets migraines.
The hazards you have to respect, though, are completely different from lithium's. Lithium's dangers are renal and toxicologic; valproate's are hematologic (thrombocytopenia), hepatic (rare fatal hepatotoxicity), pancreatic (rare pancreatitis), metabolic (weight gain), endocrine-reproductive (PCOS), and, above all, reproductive-teratogenic. Valproate is the single most teratogenic drug in the mood-stabilizer cabinet, and that fact should shape every prescribing decision you make for a woman of reproductive age.
Using valproate well means knowing exactly who it's for, loading and monitoring it correctly, catching its distinctive adverse effects early, and keeping it away from patients for whom its reproductive and cognitive-teratogenic risks make it the wrong choice. With those guardrails in place, it is reliable, effective, and mostly well tolerated.
An honest note on expectations up front: in the real world, valproate's maintenance evidence is softer than its reputation. The 12-month placebo-controlled maintenance trial of divalproex and lithium missed its primary endpoint: time to any mood episode did not differ significantly from placebo. Valproate's strongest, most defensible role is acute and mixed mania and stabilization of the unstable, irritable, rapid-cycling patient, not necessarily lifelong monotherapy prophylaxis in every bipolar patient.
How to Use Divalproex/Valproate With Confidence
Many clinicians are uneasy about valproate without having concluded it's wrong for their patient. What bothers them is a boxed-warning list that reads like a horror show: hepatotoxicity, pancreatitis, fetal toxicity. Three black-box warnings is a lot to stare at, and it's tempting to reach for something that looks simpler. This section is for the clinician who wants to use valproate but feels the pull to avoid it.
Valproate is very prescribable in any outpatient practice if you build a small, systematic routine around it. The boxed warnings sound catastrophic, but the two that most often turn lethal, fulminant hepatotoxicity and pancreatitis, are rare and largely predictable by patient selection. The teratogenicity warning is managed by not putting the drug in the wrong body, and thrombocytopenia (a labeled Warning, not a boxed warning) is managed by monitoring.
The Core Problem and Its Solution
Valproate's monitoring burden is real but modest and finite: a baseline CBC and LFTs, a serum level and platelet check a couple of weeks in, and periodic labs thereafter. In busy practices the trouble is follow-through rather than intensity: the labs get ordered and then vanish into the ether. Results don't come back, the two-week platelet check gets skipped, and the reproductive-risk conversation never quite happens.
The fix is the same one that makes lithium safe: make monitoring a shared process the patient can see, and make patient selection deliberate rather than default.
As with any narrow-therapeutic-index mood stabilizer, a shared tracking document (a Google Doc shared directly with the patient) does most of the work. Log the level, platelets, LFTs, weight, and any medication changes by date. Put the target ranges next to each value in plain language. Include the warning signs the patient is responsible for reporting: unusual bruising or bleeding, severe abdominal pain, jaundice, yellowing eyes, unusual lethargy or confusion. When the patient can see their own numbers and knows what to watch for, monitoring becomes something you do together instead of something you have to chase.
Valproate's boxed warnings are frightening in the abstract and manageable in practice. Fulminant hepatotoxicity is overwhelmingly a disease of children under 2 on anticonvulsant polypharmacy and patients with mitochondrial or urea-cycle disorders, not the healthy 35-year-old with bipolar disorder in front of you. Screen those specific risk factors out at the door, and the scariest warning largely evaporates.
Logistics
Build a standing valproate monitoring order set so the patient can walk into any lab without calling the office:
- Serum valproate level (total; free level if on aspirin or clinically indicated)
- CBC with platelets
- LFTs (AST/ALT, bilirubin)
- Baseline weight and metabolic parameters
- hCG in any woman of reproductive potential, before the first dose
Say the timing out loud and write it down: draw the level and platelets at baseline, again around 2 weeks after starting, and then periodically. Steady state arrives fast, about 2–3 days, so you can check a level within a few days of any dose change and trust it.
Addressing the Specific Fears
It is rare. It is also front-loaded (almost always in the first 6 months) and heavily concentrated in identifiable high-risk groups: very young children, anticonvulsant polypharmacy, and inborn errors of metabolism (urea cycle disorders, mitochondrial disease). Screen those out, check baseline LFTs, avoid it in hepatic disease or significant hepatic dysfunction, and educate the patient to report abdominal pain, jaundice, malaise, or unusual lethargy. That is the whole protocol.
Low platelets are common (roughly 1 in 6 epilepsy patients had at least one episode in one series) but usually mild, dose- and level-dependent, and reversible with dose reduction. You catch it with a baseline platelet count, a 2-week recheck, and periodic monitoring. It's more common in women and rises with higher serum levels (above ~110 mcg/mL in women, ~135 mcg/mL in men).
It should. The answer is to keep it from being a default choice for women of reproductive potential, not to avoid valproate universally. Valproate's ~1–2% neural tube defect rate and its dose-dependent hit to childhood IQ make it the wrong first choice in that population. For those patients, reach for lamotrigine or an atypical antipsychotic first. For men, post-reproductive women, and women on reliable contraception who've been thoroughly counseled, valproate's teratogenicity is not a bar to use.
Ammonia can rise even at therapeutic levels. You don't screen it routinely; you check it when a patient on valproate develops new lethargy, confusion, or encephalopathy, especially with a normal or unremarkable valproate level. If it's elevated, that's your explanation, and it's manageable (dose reduction, sometimes L-carnitine).
Read the three boxed warnings as instructions. Each one tells you exactly what to screen for or watch, and following them is what makes valproate safe. The hepatotoxicity warning tells you to screen out mitochondrial disease and check LFTs. The pancreatitis warning tells you to counsel about abdominal pain. And the fetal-toxicity warning tells you, loudly, to think hard before you give this drug to someone who could become pregnant. Thrombocytopenia, a labeled Warning rather than a boxed one, still earns a routine platelet check.
Do those four things and you have a fast, flexible, effective mood stabilizer that is at its best exactly where lithium is weakest.
Part 1: Indications
FDA-Approved Uses
- Acute mania in bipolar disorder (including mixed episodes)
- Migraine prophylaxis (one of the few mood stabilizers with a dual psychiatric/neurologic indication)
- Epilepsy (absence, partial, and generalized seizures)
Maintenance is missing from that list. Valproate is not established as maintenance monotherapy as firmly as lithium and lamotrigine are; it is used for maintenance in practice, but the maintenance evidence is weaker than the acute-mania evidence.
The Evidence-Based Clinical Uses
Acute and mixed mania: valproate's home turf. Among anticonvulsants, valproate and carbamazepine are the two that have "passed" controlled trials in mania; lamotrigine, gabapentin, and topiramate have failed. Valproate is fast, can be loaded, and works. It is particularly favored for the presentations where lithium is weakest:
- Mixed episodes / mixed features (dysphoric mania, depression-plus-activation)
- Rapid cycling
- Irritable or dysphoric mania rather than classic euphoric mania
- Bipolar with comorbid alcohol or substance use disorder
A simple way to divide lithium and valproate: lithium for the classic Kraepelinian patient (euphoric mania → depression → fully well between episodes); valproate for the messy patient, mixed, irritable, rapid-cycling, substance-using, or non-classic. When you can't decide, the presence of mixed features or rapid cycling tips you toward valproate.
Maintenance bipolar. Valproate is used for maintenance, but temper your expectations. In the 12-month placebo-controlled maintenance trial, divalproex did not separate from placebo on time to any mood episode, though it did beat placebo on several secondary measures. Set realistic goals with patients and consider combination therapy rather than assuming monotherapy prophylaxis will hold.
Bipolar depression: adjunctive, modest. Valproate is not a strong acute antidepressant. As an adjunct to another mood stabilizer, one line of data shows response rates around 57% for the combination vs 42% for placebo in bipolar depression. That's useful, but it's an add-on role, not monotherapy for the depressed pole.
Combination therapy. Valproate is frequently added to lithium for bipolar I (a classic, well-tolerated pairing) and used to augment antipsychotics in breakthrough mania. For the treatment-resistant bipolar I patient, adding valproate to lithium is a mainstream move.
Aggression, impulsivity, and agitation (off-label). Valproate gets a lot of real-world use here, even outside bipolar disorder:
- Borderline personality disorder: meta-analytic data show mood stabilizers including valproate have large effects on impulse control, anger, and anxiety, with moderate effects on depression and global functioning.
- Aggression in ADHD: valproate produced improvements similar to risperidone with fewer side effects.
- Agitation/aggression in schizophrenia (inpatient), TBI, developmental disability, and PTSD, commonly used, though the RCT evidence is thin and short-term benefit in some settings is "contestable."
Migraine with bipolar comorbidity. When a bipolar patient also has migraines, valproate is one option that treats both. (If there's no bipolar indication, topiramate is often preferred for migraine on tolerability grounds.)
Where Valproate Is a Poor Fit
- Bipolar II. Strong mood stabilizers like valproate can "flatten" bipolar II patients and leave them feeling depressed, especially at higher doses. Lamotrigine is the better-tolerated, depression-focused first choice here; if valproate is used in bipolar II, favor combination over monotherapy and keep doses modest.
- Behavioral/psychological symptoms of dementia (BPSD). Well-designed studies show no benefit over placebo. Don't use it here.
- Tardive dyskinesia. Limited efficacy; not a reliable treatment.
- Any woman who may become pregnant where a reasonable alternative exists (see Special Populations).
Part 2: Before You Start: Workup and Candidacy
Baseline Labs
| Test | Why |
|---|---|
| CBC with platelets | Baseline for thrombocytopenia monitoring; valproate's most common lab abnormality |
| LFTs (AST/ALT, bilirubin) | Screen for and baseline hepatic function before a drug with a hepatotoxicity boxed warning |
| hCG | In any woman of reproductive potential; this is non-negotiable given teratogenicity |
| Weight / BMI, metabolic baseline | Weight gain is common; establish a starting point |
| Creatinine / eGFR | Reasonable baseline; rare AKI reported |
What you do NOT need to check routinely: baseline amylase and lipase. The baseline is almost never abnormal, pancreatitis is rare and comes on quickly rather than gradually, and periodic screening won't reliably catch it early. Check amylase/lipase only if symptoms of pancreatitis appear (severe abdominal pain, nausea, vomiting).
Screen These Patients OUT Before Prescribing
- Hepatic disease or significant hepatic dysfunction (hepatotoxicity risk; contraindicated)
- Known or suspected mitochondrial disorders (e.g., POLG-related disorders): risk of fatal hepatotoxicity; contraindicated
- Urea cycle disorders: valproate can precipitate fatal hyperammonemic encephalopathy
- Pregnancy (especially first trimester), or a woman planning pregnancy where an alternative exists
- Children under ~2 years, especially on anticonvulsant polypharmacy (highest hepatotoxicity risk)
- Known hypersensitivity to valproate
- Bleeding disorders / significant thrombocytopenia (relative)
Patient selection removes much of the risk behind the two boxed warnings that actually kill, hepatotoxicity and pancreatitis. Fulminant hepatic failure clusters in the very young, patients on heavy polypharmacy, and those with inborn metabolic errors. Screen those groups out and check baseline LFTs, and you have dealt with the lethal end of the risk spectrum.
Part 3: How to Start and Dose
Older adultsFDA labelReduce the starting dose and raise it more slowly. Starts below 250 mg can only be achieved with Depakote DR.In practiceStart low and raise slowly; watch sedation, appetite and hydration.
Blood levelsFDA labelDepakote ER: a placebo-controlled trial of acute mania or mixed type, trough 85–125 mcg/mL. Depakote DR: placebo-controlled trials, 50–125 mcg/mL.In practiceUnder 50 is subtherapeutic. Free level (target ~5–10 mcg/mL) on aspirin or other highly protein-bound drugs, low albumin, elderly, or high totals.
Timing and missed doses4 rows
Interacting drugsFDA labelAs Depakote ER is titrated up, lamotrigine levels may be affected.In practiceValproate roughly doubles lamotrigine levels: halve the lamotrigine dose and titrate slowly (SJS risk).
Stopping2 rows
Formulations
- Divalproex sodium (Depakote): enteric-coated, delayed-release; a stable compound of valproic acid and sodium valproate. It is much gentler on the GI tract than valproic acid, which makes it your default psychiatric formulation.
- Divalproex sodium ER (Depakote ER): once-daily dosing convenience; often better tolerated. May not be covered by insurance, but is available cheaply through some programs.
- Valproic acid (Depakene): available as liquid and capsules; more GI-irritating. Its niche is settings where you must verify ingestion (e.g., correctional facilities or patients who "cheek" pills) because liquid is hard to fake. The GI irritation is an accepted tradeoff for guaranteed adherence.
- Sprinkles: useful for patients who can't swallow tablets; may reduce GI upset.
"Valproate," "valproic acid," and "divalproex" all deliver the same active moiety, the valproate ion. Divalproex (Depakote) is simply an enteric-coated, better-tolerated delivery vehicle for it. Serum levels are reported as valproate regardless of which product you used.
Free Levels: Important and Underused
Valproate is highly protein-bound (~90–95%), and only the free (unbound) fraction is pharmacologically active. In most patients the total level tracks the free level well enough. But protein binding is saturable and can be disrupted:
- In patients on aspirin or other highly protein-bound drugs, in hypoalbuminemia, in the elderly, or at high total levels, the free fraction can be dangerously high despite a normal-looking total level.
- In those situations, order a free valproate level (target ~5–10 mcg/mL) rather than trusting the total.
If a patient looks toxic (tremulous, sedated, ataxic, confused) but the total valproate level is "fine," don't be reassured. Check a free level. A normal total with a high free fraction is a classic valproate trap, and aspirin is the textbook precipitant.
Dose Adjustments and Special Populations
- Boxed warnings: (1) hepatotoxicity: rare fatal hepatic failure, highest risk under age 2 and on polytherapy; check LFTs at baseline and periodically. (2) pancreatitis: can be hemorrhagic and fatal; stop for new abdominal pain, nausea, or vomiting. (3) teratogenicity: neural-tube defects (~1–2%) and reduced IQ/neurodevelopmental harm; contraindicated for migraine prophylaxis in pregnancy and to be avoided in women of childbearing potential unless truly necessary and on effective contraception.
- Hepatic impairment: contraindicated in hepatic disease or significant hepatic dysfunction.
- Renal impairment: no major total-dose adjustment, but the free fraction rises in renal failure and hypoalbuminemia, so dose to a free level.
- Pediatric: mania efficacy is not established under age 18 (valproate is used younger for epilepsy).
Part 4: Monitoring
Core labs
| Timepoint | Draw |
|---|---|
| Baseline | CBC with platelets, LFTs, weight; hCG in women of reproductive potential |
| ~2 weeks | Platelet count (key early check), valproate level |
| First 6 months | LFTs at frequent intervals (the boxed warning, because liver failure clusters here); many clinicians check monthly |
| Periodic (q6–12 months) | CBC/platelets, LFTs, valproate level, weight |
| More frequently if | Elderly, bleeding disorder, high levels, hepatic risk, clinical concern |
What to watch clinically (not by routine lab)
- Hepatotoxicity: highest risk in the first 6 months, which is why the boxed warning asks for LFTs at frequent intervals then. Educate the patient to report abdominal pain, nausea/vomiting, jaundice, malaise, unusual lethargy. Check LFTs if symptoms arise.
- Pancreatitis: don't screen amylase/lipase routinely; check only if abdominal pain develops.
- Hyperammonemia: don't screen routinely; check an ammonia level if new confusion, lethargy, or encephalopathy appears, even with a normal valproate level. The label also asks for an ammonia level when topiramate is added, because the pair can cause hyperammonemia and hypothermia in people who tolerated either drug alone.
- Hypersensitivity reactions: the label warns of DRESS (fever, rash, lymphadenopathy, organ involvement), serious skin reactions including Stevens-Johnson syndrome, and angioedema. Stop at the first rash unless it is clearly not drug related, and stop at once for swelling of the face, mouth or airway.
- Suicidal thoughts: antiepileptic drugs, valproate included, carry a label warning for suicidal thoughts and behavior. Ask about new or worsening mood changes and suicidal thinking at visits.
- Alcohol: the label says not to drink alcohol on valproate; the two add to sedation and dizziness.
- PCOS (women 18–44): monitor menstrual regularity, hirsutism, acne; check testosterone if symptoms emerge.
- Weight: track at every visit; it's one of the more common reasons patients quit.
Thresholds to act on
- Platelets <150,000/μL: thrombocytopenia. Mild and asymptomatic → monitor and often reduce dose (especially if level is high). Significant or symptomatic (bruising, bleeding, petechiae) → reduce dose or discontinue.
- Rising transaminases: mild, asymptomatic elevations are common and often tolerable; symptomatic elevation, jaundice, or rapidly rising LFTs → stop and evaluate for hepatotoxicity.
- New encephalopathy with normal VPA level: check ammonia.
- PCOS symptoms: counsel, check testosterone, and consider switching agents.
Part 5: Side Effects and How to Manage Them
As with lithium, most valproate side effects are dose- and level-dependent, most are manageable, and side effects, not lack of efficacy, are the usual reason patients quit. But the specific menu is entirely different from lithium's.
Gastrointestinal (nausea, dyspepsia)
Common early, especially with valproic acid.
Management:
- Use enteric-coated divalproex (Depakote), not valproic acid (Depakene). No other change does more for GI tolerability.
- Consider ER or the sprinkles formulation.
- Take with food; titrate more slowly.
Hematologic: Thrombocytopenia
Not rare. Roughly 17.7% (about 1 in 6) of epilepsy patients had at least one episode of thrombocytopenia (platelets <150,000/μL) in one 265-patient series.
- More common in women.
- Level-dependent: risk climbs above ~110 mcg/mL in women, ~135 mcg/mL in men.
- Valproate can also cause platelet dysfunction (impaired function even with an adequate count), relevant before surgery.
Management:
- Baseline platelets → 2-week recheck → periodic.
- Counsel on bruising/bleeding.
- Mild/asymptomatic: monitor, often lower the dose (which lowers the level).
- Significant/symptomatic: reduce dose or discontinue; consider hematology if severe.
Metabolic: Weight Gain
Common and a major adherence problem.
- Occurs in ~20–25% of patients; typically 3–10 kg over 3–12 months. Some long-term epilepsy data are more dramatic (mean gain of ~21 kg in a subset of women over years).
- In women, weight gain and PCOS can feed each other.
Management:
- Diet and activity counseling from the start; set expectations.
- If the patient is also on a metabolically costly antipsychotic, trim the antipsychotic first: it's usually the bigger culprit.
- Consider metformin as an adjunct in patients gaining significant weight.
Endocrine/Reproductive: PCOS (Women 18–44)
A confirmed risk characteristic of valproate, and one clinicians routinely underappreciate. In Joffe's prospective study of 300 women at 16 STEP-BD sites, new-onset oligoamenorrhea with hyperandrogenism developed in 10.5% of women on valproate (9 of 86) vs 1.4% on a non-valproate anticonvulsant or lithium (2 of 144), a relative risk of 7.5 (95% CI 1.7 to 34.1).
- Features: menstrual irregularity, hirsutism, acne, male-pattern hair loss, elevated testosterone.
Management:
- Warn women of reproductive age before starting. This is a consent-level disclosure.
- Monitor menstrual regularity, hirsutism, acne; check testosterone if symptoms develop.
- If PCOS emerges, consider switching agents and involve gynecology.
Dermatologic/Cosmetic: Hair Loss (Alopecia)
Clinically significant and distressing, though poorly studied. Thought to relate to impaired absorption of trace micronutrients.
Management (a useful practical protocol):
- Supplement zinc (~22 mg, chelated), selenium (~200 mcg), and biotin (~10 mg) daily.
- Biotin at that dose can distort immunoassays built on biotin-streptavidin binding, including troponin and thyroid tests, in either direction. Tell the lab the patient is taking it, and question a result that does not fit the clinical picture.
- Take supplements at a different time of day than the valproate, because the drug interferes with their absorption.
- Reassure: follicles aren't destroyed, so hair regrows if the supplements work or the drug is stopped.
- No single multivitamin carries these at adequate doses, so they must be taken separately.
Neurological: Tremor and Sedation
- Tremor: often dose-related; lower the dose, and propranolol can be used as with other action tremors.
- Sedation/drowsiness: variable; often improves with time or with dose/timing adjustment.
Cognitive/CNS
- Valproate has GABAergic activity, and one case report links it with sleepwalking alongside zolpidem (resolved on dechallenge). Note it and watch; it is not a hard stop.
Sexual
- Sexual side effects are possible but tend to be less than with enzyme-inducing anticonvulsants (carbamazepine, oxcarbazepine), which raise SHBG and lower free testosterone. Because valproate doesn't induce enzymes, it is comparatively easier on sexual function.
Cardiac
- Valproate is relatively safe for cardiac conduction. Its sodium channel action is a neuronal one, and it does not carry the cardiac sodium channel blockade that can slow ventricular conduction and widen the QRS, as carbamazepine and lamotrigine do, so it is a reasonable choice in patients with conduction concerns.
Part 6: Toxicity and the Boxed Warnings
Valproate carries three FDA boxed warnings. Know them cold.
- Hepatotoxicity. Rare but potentially fatal, with risk highest in the first 6 months. Concentrated in identifiable groups: children under 2, patients on anticonvulsant polypharmacy, and those with mitochondrial disorders or other inborn metabolic errors. Contraindicated in hepatic disease or significant hepatic dysfunction. Check baseline LFTs, educate on symptoms (abdominal pain, jaundice, malaise, lethargy, anorexia), and stop and evaluate for symptomatic elevation or clinical hepatitis.
- Pancreatitis. Rare, can be hemorrhagic and life-threatening, and can occur at any point in treatment. Don't screen amylase/lipase routinely; it won't catch it. Counsel patients to report severe abdominal pain, and check enzymes promptly if symptoms appear.
- Fetal toxicity (teratogenicity). The most consequential warning for a psychiatric prescriber; a decisive factor in agent selection for anyone who could become pregnant (see Special Populations).
Thrombocytopenia and platelet dysfunction are dose- and level-dependent adverse effects (a labeled Warning, not a boxed warning); monitor platelets (see Part 5 for the specific thresholds and management).
Overdose and acute toxicity
- Signs of high levels: somnolence, ataxia, tremor, confusion, and at the extreme coma.
- Hyperammonemia can occur even at therapeutic levels and cause encephalopathy; check ammonia in any valproate patient with unexplained new confusion or lethargy.
- Valproate has a narrow therapeutic index; modest level changes can matter. Manage overdose supportively; severe cases may involve the ED, and L-carnitine is used for valproate-induced hyperammonemia and serious toxicity.
A patient stable on valproate develops progressive confusion or lethargy, and the valproate level comes back "therapeutic." The instinct is to look elsewhere. Check an ammonia level. Valproate-induced hyperammonemic encephalopathy can occur with a perfectly normal valproate level, and it's reversible (dose reduction, sometimes L-carnitine) once you name it.
Part 7: Drug Interactions
Valproate is metabolized hepatically (largely by mitochondrial β-oxidation and glucuronidation), with limited CYP450 involvement compared with carbamazepine. Its interactions cluster in three buckets: protein-binding displacement, the lamotrigine interaction, and level-based additive effects.
The lamotrigine interaction
This is the interaction you must not miss. Valproate roughly DOUBLES lamotrigine levels by inhibiting lamotrigine's glucuronidation (UGT1A4). This is a major, clinically dangerous interaction because it directly raises the risk of Stevens-Johnson syndrome on lamotrigine.
- When adding lamotrigine to a patient on valproate, use the reduced lamotrigine titration schedule (roughly half the usual doses) and titrate especially slowly.
- This is one of the most tested, most consequential interactions in bipolar pharmacology. Get it wrong and you can cause a life-threatening rash.
Protein-binding displacement
- Aspirin (and other highly protein-bound drugs) displace valproate from serum proteins, raising the free (active) fraction, with potential toxicity despite a normal total level.
- Management: in patients on aspirin or with hypoalbuminemia, order a free valproate level rather than trusting the total.
Valproate as an inhibitor (levels of other drugs rise)
- Topiramate: the combination can cause hyperammonemia, with or without encephalopathy, and hypothermia, even in people who tolerated each drug alone. Check an ammonia level for lethargy, vomiting or confusion.
- Valproate can raise the levels of some antipsychotics and other co-prescribed psychotropics. Watch for additive sedation or increased side effects when combining.
- With zolpidem the evidence is a single case report of sleepwalking that stopped on dechallenge: note and watch, not a hard stop.
Drugs that lower valproate levels
- Enzyme inducers (carbamazepine, rifampin, phenytoin, phenobarbital) reduce valproate levels by speeding its glucuronidation: watch for loss of efficacy when they're co-prescribed, and for level swings when they're started or stopped.
Folic acid and l-methylfolate
- Folic acid may augment valproate (and antidepressants), but in patients also on lamotrigine, folic acid can nullify lamotrigine's benefit in a genetically defined subset (COMT-related). l-Methylfolate (the CNS-active form) does not appear to carry this interaction and is the safer supplement in a lamotrigine-treated patient.
Narrow therapeutic index
- Like lithium, tricyclics, and carbamazepine, valproate has a narrow therapeutic index: modest level differences can have outsized effects. Respect the level.
Part 8: Special Populations
Pregnancy: The Defining Risk
Valproate is the most teratogenic mood stabilizer, and this fact should govern agent selection for anyone who could become pregnant.
- Neural tube defects: ~1–2%, against a general-population spina bifida rate of about 0.06–0.07%.
- Other anomalies (2–7× risk): atrial septal defects, hypospadias, cleft palate, polydactyly, craniosynostosis.
- Neurodevelopmental toxicity: children exposed, even after the first trimester, show lower IQ and poorer cognitive outcomes than children exposed to other antiepileptic monotherapies or none. The harm is a whole-pregnancy cognitive problem, not only a first-trimester structural one.
Prevention efforts have limited efficacy:
- High-dose folic acid (4–5 mg/day): did not reduce the birth-defect rate in one study (though it reduced miscarriage risk). Don't count on folate to make valproate safe in pregnancy.
In practice:
- Avoid valproate in pregnancy, especially the first trimester.
- For a bipolar woman of reproductive age who needs a mood stabilizer, prefer lamotrigine or an atypical antipsychotic. Even lithium, despite its heavier monitoring burden, is substantially safer teratogenically than valproate.
- If a patient of reproductive potential is on valproate, ensure reliable contraception and a documented risk conversation, and revisit the agent choice at every opportunity.
Weigh this against the real danger of untreated illness: in one cohort of 89 pregnant bipolar women, 70% stopped mood stabilizers and were more than twice as likely to relapse (85% vs 37%), and abrupt discontinuation caused far faster relapse (~2 weeks) than gradual (~22 weeks). The lesson isn't "keep valproate"; it's to switch to a safer agent well before conception rather than stopping cold.
Breastfeeding
- Considered relatively safe: valproate levels in breast milk are low.
- Residual concerns: theoretical infant hepatotoxicity and a questionable reported case of infant thrombocytopenia.
- If the mother breastfeeds, watch the infant for unusual bruising or bleeding, and consider checking infant valproate level, platelets, and LFTs if there's any concern.
Elderly
- Start at a reduced dose and raise it more slowly: unbound clearance falls with age and older patients are more sensitive to somnolence.
- Watch thrombocytopenia and hyponatremia more vigilantly.
- Free-level considerations matter more (lower albumin, polypharmacy): check free levels when toxicity is suspected but the total looks normal.
Renal Impairment
- Rare valproate-associated acute kidney injury is reported. In a Stockholm cohort of 10,946 patients, 10-year kidney outcomes were similar on valproate and lithium, with CKD progression at 8.2% and 8.4% respectively.
- Baseline creatinine/eGFR is prudent; avoid in severe renal disease.
Hepatic Impairment
- Contraindicated in hepatic disease or significant hepatic dysfunction.
- Rare but potentially fatal hepatotoxicity, concentrated in the first 6 months and in high-risk groups; monitor LFTs closely, particularly on polypharmacy.
Pediatric
- Epilepsy indications are established; bipolar use is off-label.
- Highest hepatotoxicity risk is in children under 2 on polypharmacy, a group to avoid.
- Any female pediatric patient reaching reproductive age inherits the full teratogenic risk; factor this into long-term planning.
Part 9: Discontinuation
Valproate doesn't have lithium's dramatic, well-quantified rebound, and there is no rigid FDA-mandated taper. Still, do not stop it abruptly in a mood-disorder patient. As a general mood-stabilizer principle, abrupt discontinuation drives faster relapse than gradual withdrawal.
- Taper gradually rather than stopping cold. There is no established schedule for valproate, so set the pace by the patient's clinical stability rather than a fixed percentage.
- The pregnancy data show how much this matters: abrupt cessation triggered relapse in ~2 weeks vs ~22 weeks for gradual cessation. If you're stopping for pregnancy planning, switch or taper deliberately and ahead of time, not reactively.
- A special caution when co-prescribed with lamotrigine: because valproate doubles lamotrigine levels, stopping valproate will roughly halve the lamotrigine level. Anticipate loss of lamotrigine efficacy and adjust the lamotrigine dose upward as you withdraw the valproate. (And if lamotrigine has been off for more than ~5 days for any reason, it must be re-titrated from the start to avoid rash.)
- The message to patients: "It's far easier to prevent a relapse than to treat an episode, so we taper slowly, and we never stop on our own."
Part 10: Valproate vs the Alternatives
- vs Lithium. Similar short-term antimanic efficacy; lithium is superior as monotherapy in classic bipolar I (and uniquely reduces suicide), while valproate is preferred for mixed features, rapid cycling, and comorbid substance use. Both carry comparable renal risk (10-year CKD progression 8.2% on valproate vs 8.4% on lithium in the Stockholm cohort, with no significant difference in acute kidney injury). Lithium needs more intensive monitoring (levels, renal, thyroid); valproate avoids the renal/thyroid worry but adds hepatic, hematologic, and metabolic ones. Lithium is substantially safer in pregnancy, where its cardiac malformation risk sits well below valproate's ~1–2% neural tube defect risk. Lithium + valproate is a mainstream, effective combination for resistant bipolar I.
- vs Lamotrigine. Lamotrigine is the better maintenance and depression-prevention agent and the far better tolerated one (no weight gain, no PCOS), and it is much safer in pregnancy (~2.2% defect rate, within baseline). Valproate is better for acute/mixed mania, which lamotrigine does not treat. Remember the interaction: valproate doubles lamotrigine, so combining them demands a reduced lamotrigine titration.
- vs Carbamazepine. Both "pass" in mania. Carbamazepine is a potent CYP3A4 inducer with a heavy interaction burden and hematologic risks (agranulocytosis, aplastic anemia); valproate's interaction profile is lighter and it doesn't cause those hematologic catastrophes. Both are teratogenic (NTDs).
- vs Atypical antipsychotics. Antipsychotics are safer in pregnancy and are preferred first-line for reproductive-age women; they also act fast in acute mania. Valproate is favored for non-psychotic mixed/rapid-cycling presentations and for agitation across diagnoses.
Where valproate wins: speed and loadability in acute/mixed mania; the messy, non-classic, rapid-cycling, substance-using bipolar patient; the bipolar-plus-migraine patient; agitation and impulsivity across diagnoses; and a comparatively clean cardiac-conduction and drug-interaction profile.
Where valproate loses: any woman who might become pregnant (teratogenicity + IQ effects); bipolar II (flattening); pure maintenance monotherapy (soft evidence); and patients where weight gain or PCOS would be especially costly.
Mechanism
Valproate's mood mechanism is not fully understood, but the leading actions are:
- Enhanced GABA neurotransmission (increased GABA synthesis, reduced catabolism): the classic account.
- Blockade of voltage-gated sodium channels (shared with other anticonvulsants).
- Histone deacetylase (HDAC) inhibition: an emerging epigenetic mechanism that may contribute to mood stabilization and neuroprotection.
Pharmacokinetics that shape prescribing:
- Half-life ~8–17 hours → BID or TID dosing for standard forms, once-daily for ER.
- Protein binding ~90–95%, saturable → the free-fraction traps described above.
- Hepatic metabolism (mitochondrial β-oxidation, glucuronidation) → the hepatotoxicity and hyperammonemia risks, and the lamotrigine (UGT) interaction.
- Steady state ~2–3 days → fast level feedback, and the ability to load in acute mania.
Valproic acid was synthesized in 1882 as a simple fatty acid and for decades was used only as an inert organic solvent. Then, in 1960s Grenoble, compounds dissolved in it were noticed to have anticonvulsant effects that turned out to come from the solvent itself. Abbott later created divalproex (Depakote) as a better-tolerated formulation.
Bedside Cheat Sheet
Starting
- Default to enteric-coated divalproex (Depakote); use ER for once-daily, valproic acid (Depakene) only when you must verify ingestion
- Start 250–500 mg BID; target ~15–20 mg/kg/day (~1,000–1,500 mg/day). Load in acute mania when speed matters
- Baseline labs: CBC/platelets, LFTs, weight, hCG (women of reproductive potential)
Levels
- Target 50–125 mcg/mL for mania (the Depakote ER mania trial dosed to troughs of 85–125 mcg/mL)
- Steady state ~2–3 days: check a level a few days after any change
- Toxic-looking patient with a "normal" total level → check a FREE level (esp. on aspirin)
Monitoring
- Platelets at baseline and ~2 weeks, then periodically; watch levels >110 (women)/>135 (men)
- LFTs at baseline and at frequent intervals in the first 6 months (boxed warning), then every 6–12 months
- Don't screen amylase/lipase or ammonia routinely: check them when symptoms appear (abd pain → pancreatitis; new confusion/lethargy → ammonia)
- Women 18–44: monitor for PCOS (menses, hirsutism, acne, testosterone)
Side effects
- GI: switch valproic acid → enteric-coated Depakote; ER or sprinkles
- Hair loss: zinc 22 mg + selenium 200 mcg + biotin 10 mg, taken at a different time than the drug (biotin distorts troponin and thyroid immunoassays: tell the lab)
- Weight gain (~20–25%): diet/activity; trim any antipsychotic first
- Thrombocytopenia: lower dose (lowers level)
Don't forget
- Valproate DOUBLES lamotrigine: use the reduced lamotrigine titration; SJS risk if you don't
- Teratogenic (~1–2% NTD, 10–20× lithium) + lowers child IQ: avoid in anyone who might become pregnant; prefer lamotrigine or an atypical
- Three boxed warnings: hepatotoxicity, fetal toxicity, pancreatitis (thrombocytopenia is a labeled Warning, not a boxed warning)
- Not for bipolar II (flattening); no benefit in dementia agitation (BPSD)
- Hyperammonemic encephalopathy can occur with a normal valproate level
Lithium rewards the classic, well-demarcated bipolar patient with unmatched depth of evidence and a unique anti-suicide effect. Valproate is lithium's pragmatic counterpart, and it handles the patients real practice actually delivers: mixed, irritable, rapid-cycling, substance-using, migrainous, agitated. It loads fast and doses flexibly. Its monitoring looks daunting on paper but reduces to a short, learnable routine: check platelets and LFTs, respect the free-level traps, watch the weight, and mind the lamotrigine interaction. What it demands without compromise is respect for its reproductive toxicity. Valproate is the most teratogenic drug in the mood-stabilizer cabinet, and it dulls the developing brain even beyond the first trimester, so keep it out of bodies that might carry a pregnancy when a reasonable alternative exists. Also screen out the small groups vulnerable to its lethal hepatic and pancreatic effects. Do both and you have a fast, flexible, effective stabilizer for the bipolar patient who doesn't read the textbook.